Search company, investor...


Founded Year




Date of IPO


About SpectraCure

SpectraCure focuses on cancer treatments using medical systems with laser light sources and reactive drugs, which are referred to as "Interstitial Photodynamic Therapy", PDT, a treatment methodology suitable for internal solid tumours of various kind, e.g. prostate and abdominal salivary glands, but also other indications such as cancer of the head and neck.

Headquarters Location

Magistratsvägen 10

Lund, 226 43,


+46(0)46-16 20 70

Missing: SpectraCure's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: SpectraCure's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing SpectraCure

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

SpectraCure is included in 2 Expert Collections, including Medical Devices.


Medical Devices

8,633 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Health IT

7,901 items

SpectraCure Patents

SpectraCure has filed 6 patents.

The 3 most popular patent topics include:

  • Electromagnetic radiation
  • Luminescence
  • Medical physics
patents chart

Application Date

Grant Date


Related Topics




Spectroscopy, Medical physics, Radiation therapy, Luminescence, Electromagnetic radiation


Application Date


Grant Date



Related Topics

Spectroscopy, Medical physics, Radiation therapy, Luminescence, Electromagnetic radiation



Latest SpectraCure News

Positive feedback from treatment with SpectraCure’s system Q-PRO® in New York

Feb 2, 2023

Positive feedback from treatment with SpectraCure’s system Q-PRO® in New York Thu, Feb 02, 2023 14:40 CET In the ongoing clinical study, the first treatment with the new generation of SpectraCure's system Q-PRO® with integrated image processing technology was performed in November. The procedure went according to plan, and the system met the highly set expectations. Dr. James A. Eastham is the investigator at MSKCC in New York and the first Doctor to use the new generation of SpectraCure’s Q-PRO® treatment system in the clinical study. Dr. Eastham is a surgeon who specializes in nerve-sparing prostatectomy for the treatment of prostate cancer and salvage radical prostatectomy in patients with prostate cancer in whom radiation therapy has failed. The company has received positive feedback regarding the usability of SpectraCure’s Q-PRO® system after the first treatment at MSKCC. ”The SpectraCure system is user-friendly,” said Doctor James A. Eastham. “Anyone familiar with transperineal prostate biopsy or prostate brachytherapy will be comfortable with the device. Overall, technically very simple and fortunately well-tolerated by the patient. Looking forward to using the SpectraCure system soon.” “It is very encouraging that the new system was well-received by Dr. Eastham and his team at MSKCC, and equally encouraging that the first patient treated with the system is well,” says Johannes Swartling, CTO at SpectraCure. “The main goal of the clinical trial is, of course, to evaluate the medical aspects of the treatment, but evaluating the usability of the system is also required, and this is an important step in this work.” For further information: SpectraCure is developing a treatment system for the elimination of internal solid cancer tumors. We are initially focusing on recurrent prostate cancer, hoping to treat other cancers such as primary prostate cancer, breast cancer, pancreatic cancer, and head and neck cancer in the future. The approach is based on a proprietary and patented treatment system, Q-PRO®, consisting of a hardware device and a laser unit, which performs PDT treatment and treats the prostate itself, combined with a software device, the patented IDOSE® dose planning platform. The method allows the laser light dose to be controlled so that the tumour is exposed to an optimal dose to achieve sufficient treatment effect. The treatment system has the potential to make interstitial PDT treatment accurate, precise, safe for every patient. The goal is that in addition to being tumor free, the patient will be able to maintain their quality of life, with limited side effects. We are conducting clinical trials as an important part of the continued development of the company's treatment system. The company is listed in the Premier segment of the Nasdaq First North Growth Market with G&W Fondkommission as Certified Adviser, and trades under the short name SPEC.

SpectraCure Frequently Asked Questions (FAQ)

  • When was SpectraCure founded?

    SpectraCure was founded in 2003.

  • Where is SpectraCure's headquarters?

    SpectraCure's headquarters is located at Magistratsvägen 10, Lund.

  • What is SpectraCure's latest funding round?

    SpectraCure's latest funding round is IPO.

  • Who are the investors of SpectraCure?

    Investors of SpectraCure include Karolinska Development, Lunds Universitets Innovation System, Teknoseed and Industrifonden.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.